FiercePharma

RELVAR® ELLIPTA® receives European marketing authorisation for the treatment of asthma and COPD

LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA--(Marketwired - Nov 18, 2013) - GlaxoSmithKline plc (GSK) and Theravance, Inc. (NASDAQ: THRX) announced today that the European Commission has ...
FiercePharma

RELVAR™ ELLIPTA™ gains approval in Japan for the treatment of asthma

GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved RELVAR™ ELLIPTA™ for the treatment ...
Insider Monkey

Relvar Ellipta: GlaxoSmithKline and Theravance’s Drug for Respiratory Diseases

Relvar Ellipta: Over the past few days, research-based pharmaceutical GlaxoSmithKline plc (ADR) (NYSE:GSK) and biopharmaceutical company Theravance Inc (NASDAQ:THRX)’s Relvar Ellipta has been in the ...
The Financial

Relvar Ellipta 100/25 mcg gains approval in Japan for use in patients with COPD

The FINANCIAL — GlaxoSmithKline plc on December 2 announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Relvar Ellipta (fluticasone furoate / vilanterol 100/25 mcg) ...
Pharmabiz

EU approves label update to Relvar Ellipta in patients with asthma

GlaxoSmithKline plc (GSK) and Innoviva, Inc. announced that the European Commission has approved a label update for the use of once-daily Relvar Ellipta (fluticasone furoate/vilanterol, FF/VI), an ...